Laboratorio Cristalia

What Laboratorio Cristalia does

Laboratorio Cristalia is a 100% Brazilian pharmaceutical, pharmochemical, biotechnological, and research/development/innovation industrial complex headquartered in Itapira, São Paulo, founded in 1972 by Dr. Ogari de Castro Pacheco. The company operates three business lines — Hospital, Pharma Medications, and Ophthalmology (via the 2015-acquired Latinofarma brand) — with a portfolio of approximately 350 medications in roughly 500 pharmaceutical forms, including proprietary molecules such as S-cetamina, Helleva, Alimax, and the clinical-stage Polilaminin. Cristalia is the largest producer of anesthetics in Latin America, supplies approximately 95% of Brazilian hospitals, produces 60% of its own Active Pharmaceutical Ingredients (versus a Brazilian industry norm of 10% self-production), and operates two biotechnology plants using genetically modified cell culture technology, with a third biotech plant under construction at Montes Claros.

The company's business model combines B2B pharmaceutical product sales (institutional hospital supply, retail pharmacy distribution across 65+ outlets, and government/SUS procurement), licensing and technology-transfer fees from 25 public-private partnerships (including somatropin transfer to Bio-Manguinhos/Fiocruz), and proprietary API production. GTM is sales-led via a direct sales force and an IQVIA-powered Virtual Representative program, supported by medical congresses, PR, and a multilingual website (Portuguese, English, Spanish). Revenue is generated across domestic sales, export to more than 30 countries with 300 international product registrations, and government contracting, with no publicly disclosed pricing.

Recent strategic activity centers on major capacity build-out: Unit IX in Montes Claros (MG, 2025) with up to 2 billion tablets per year, the Applied Genetics laboratory in Campinas (June 2026), and an R$350 million third biotechnology plant. The company has self-funded cumulative capex of more than R$650 million across Polilaminin (R$100M+), the new biotech plant (R$350M), and prior R&D Center investments (R$30M in 2010). With approximately 2,000 direct employees and 131 granted patents across Brazil, the EU, the US, and 11 other countries, Cristalia is the only Brazilian laboratory with complete vertical integration from molecule conception through finished pharmaceutical product.

Name

Laboratorio Cristalia

Legal name

Cristália Produtos Químicos Farmacêuticos Ltda.

Website

https://cristalia.com.br

Company type

Private

Founded year

1972

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Laboratorio Cristalia is a 100% Brazilian pharmaceutical and biotech company that develops, manufactures, and supplies approximately 350 medications across hospital, retail, and ophthalmology segments, serving roughly 95% of Brazilian hospitals and exporting to 30+ countries with full vertical API integration.

Ownership category

akta.pro rank

Product category

Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Generic Hospital & Institutional Products (HLAIABAL)

akta.pro secondary industries

Pain Management & Anesthesiology Pharmaceuticals (HLAIAAAN), Drug Product Fill-Finish & Aseptic Manufacturing Services (HLAAAKAB), Raw Materials & Critical Reagents Supply Services (media, resins, single-use) (HLAAAKAI)

Keywords

• Pharmaceutical manufacturing
• Active pharmaceutical ingredients
• Hospital medications
• Biotechnology production
• Anesthetic medications

Headquarters

HQ city

Itapira

HQ country

Brazil

HQ region

Latin America

Offices8 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Technology or R&D, Personnel, Infrastructure, Marketing or Sales

Revenue model

1. Pharmaceutical Product Sales: Sale of 350 medications in approximately 500 pharmaceutical forms across Hospital, Pharma Medications, and Ophthalmology segments. Supplies approximately 95% of Brazilian hospitals.
2. Active Pharmaceutical Ingredient (API) Production: Cristália produces 60% of its own API needs, differentiating from Brazilian industry that imports 90% of IFAs. Includes pharmochemical and oncological pharmochemical production.
3. Technology Transfer: Public-private partnerships transferring technology to government laboratories. 25 PD&Is with Federal Government to transfer technology to public laboratories. Includes somatropin technology transfer to Bio-Manguinhos/Fiocruz benefiting 30,000+ patients.
4. Biotechnology Manufacturing: Pioneer in biotechnology with two manufacturing plants for biological pharmaceutical inputs. Produces biological medications through genetically modified cell culture technology.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels6 records

Core offering

Laboratorio Cristalia manufactures and sells approximately 350 medications in about 500 pharmaceutical forms across three business lines — Hospitalar (hospital injectables, anesthetics, narcoanalgesics, anti-infectives, intensive care), Farma Medicamentos (mental health, dermatology, pain, OTC), and Oftalmológica (eye drops and artificial tears). The company is vertically integrated, producing 60% of its own Active Pharmaceutical Ingredients and operating two biotechnological plants, making it the largest producer of anesthetics in Latin America supplying 95% of Brazilian hospitals.

Product overview

Laboratório Cristália is a 100% Brazilian pharmaceutical, pharmacochemical, biotechnological, and research/development/innovation complex. The company operates three main business lines: Hospital (hospitalar), Pharma Medications (farma medicamentos), and Ophthalmology. The portfolio consists of approximately 350 medicines in about 500 pharmaceutical forms, supplied to about 95% of Brazilian hospitals. Cristália is recognized for its innovative products in Anesthetics and Narcoanalgesics, Pain, Inflammation, Mental Health, Therapeutic and Cosmetic Dermatology, Antiretrovirals/HIV, OTC, Ophthalmological drops, and Artificial Tears. The company also operates a pharmacochemical division producing 60% of its own Active Pharmaceutical Ingredients (IFAs), and a biotechnology division developing biological medicines through genetically modified cell culture. Key products include Polilaminina (in clinical trials for spinal cord injury), Helleva (erectile dysfunction), Alimax (burns treatment), and S-cetamina (anesthetic). The Latinofarma ophthalmology division was acquired in 2015 to strengthen the ophthalmological segment.

Differentiator

Problem solved

Functional benefit

Brands

• Latinofarma: Ophthalmology division of Cristália, acquired in 2015 and incorporated in 2018, focusing on ophthalmological products.
• HEMOFOL
• Polilaminina (Polylaminin)

Products and services

• Polilaminina (Polylaminin) A 100% Brazilian breakthrough polymerized version of laminin extracted from human placenta for treatment of spinal cord injuries. Currently in Phase 1 clinical trials authorized by ANVISA on January 5, 2026. The product is being developed through a research partnership with UFRJ, with approximately R$100 million invested to date and patent protection effective until 2042 (national) and 2043 (global).
• Helleva

Quantifiable outcome

• Supplies 95% of Brazilian hospitals with medications
• +3 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Nine partnerships are on record, tiered core and minor.

• Universidade Federal do Rio de Janeiro (UFRJ)coreStrategic or Co-development Partner · 9 June 2026Research partnership with Professor Tatiana Coelho Sampaio's team for Polilaminina development. UFRJ developed the initial scientific research over 20+ years. Cristália established collaboration in 2021 to enable large-scale development and manufacturing. R$100 million invested in the project.
• Bio-Manguinhos/FiocruzcoreStrategic or Co-development Partner · 1 January 2022Technology transfer of somatropin biological medication completed in 2022. Second phase of technology transfer completed, benefiting more than 30,000 patients with growth hormone deficiency treatment.
• IQVIAcoreTechnology or Integration · 1 January 2022Virtual Representative project partnership where IQVIA acts as independent data controller for selection and collection of physician data for remote sales promotion activities. IQVIA responsible for selecting and collecting personal data of participating doctors.
• LatinofarmacoreOEM/ Whitelabel/ Licensing Partner · 1 January 2015Acquisition of Latinofarma in 2015 strengthening ophthalmology segment. Company officially incorporated into Cristália on January 1, 2018.
• BahiafarmacoreStrategic or Co-development Partner · 1 January 2011Public-private partnership for production and technology transfer of medications for chronic kidney disease (sevelamer) and hormonal imbalance (cabergolina). Part of R$35 million investment plan for reactivation of the Bahia state pharmaceutical laboratory.
• Laboratório Farmacêutico da Marinha (LFM)coreStrategic or Co-development Partner · 1 January 2011Public-private partnership with Navy Pharmaceutical Laboratory for production of arthritis (leflunomide) and chronic sclerosis (riluzole) medications through technology transfer.
• FarmanguinhoscoreStrategic or Co-development Partner · 1 January 2011Partnership with Farmanguinhos/Fiocruz for technology transfer and production of antiretroviral medications and other treatments including tenofovir (50% of national production).
• ActelionminorStrategic or Co-development Partner · 1 January 2010Partnership with Swiss pharmaceutical company Actelion to develop and promote a medication in Brazil. One of few Brazilian laboratories investing in innovation partnering with international company.
• NANJING King-Friend Biochemical Pharmaceutical Co. LtdcoreOthers · 1 January 2010Chinese supplier of heparin active pharmaceutical ingredient. Supplier's production line approved by FDA. Technical partnership allowed production of high-purity heparin (HEMOFOL).

Scale indicators11 records

Recent moves11 records

Expansion highlights5 records

Direct peers

• EMS Pharma: EMS is the largest pharmaceutical company in Brazil by revenue, with a broad portfolio of branded generics, hospital, and OTC products. Direct comparable to Cristália as a domestic Brazilian pharma with deep hospital and retail channel coverage, vertical integration ambitions, and innovation pipeline.
• Aché Laboratórios Farmacêuticos: Aché is a leading Brazilian pharmaceutical manufacturer with a strong prescription, OTC, and hospital portfolio and a meaningful innovation pipeline. Comparable to Cristália as a domestic Brazilian pharma with hospital presence, R&D investment, and consumer health adjacencies.
• Eurofarma Laboratórios: Eurofarma is a top-3 Brazilian pharmaceutical company with a hospital, retail, and specialty care portfolio, plus significant international operations across Latin America. Highly comparable to Cristália in vertical integration strategy, hospital segment focus, and expansion into biotechnology and innovation.
• Biolab Farmaceutica: Biolab is a Brazilian pharmaceutical company focused on prescription drugs, hospital specialty products, and innovation. Comparable to Cristália in hospital channel focus, mid-size domestic pharma profile, and investment in proprietary molecules.
• Apsen Farmacêutica: Apsen is a mid-sized Brazilian pharmaceutical company with a strong neurology, psychiatry, and specialty prescription portfolio. Comparable to Cristália in being a privately held, founder-influenced Brazilian pharma with branded specialty products.

Broad incumbents

• Hypera Pharma: Hypera (formerly Hypermarcas) is the largest Brazilian OTC and consumer health company with a broad branded portfolio. Comparable to Cristália as a major Brazilian pharma operator, though Hypera is OTC-led whereas Cristália is hospital-led.
• Baxter International: Baxter is a global hospital products and injectable pharmaceuticals company with strong anesthetic, critical care, and sterile manufacturing capabilities. Comparable to Cristália in the hospital injectables and anesthetics category, though at much larger global scale.

Regional players

• Dr. Reddy's Laboratories: Dr. Reddy's is an India-headquartered global pharmaceutical company with strong API manufacturing and finished dosage form businesses across emerging markets. Comparable to Cristália in vertical API integration, emerging-market hospital focus, and investment in biosimilars and complex generics.
• Medley (Sanofi Brasil): Medley is Sanofi's Brazilian generics subsidiary with a large hospital and retail portfolio. Comparable to Cristália as a Brazilian generic and hospital-focused player, though owned by a global pharma parent with different capital structure.

Others

• Bio-Manguinhos/Fiocruz: Bio-Manguinhos is the public pharmaceutical arm of Brazil's Fiocruz foundation, focused on vaccines and biopharmaceuticals and a technology transfer partner/recipient of Cristália. Comparable as a Brazilian biopharma counterparty rather than a direct competitor, and a key institutional channel for Cristália.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights8 records

Customer concentration

• YouTubeyoutube.com/channel/UC6hPRXn5wCLH9WJjtqRCX5g
• Facebookfacebook.com/LaboratorioCristalia
• Xx.com/LabCristalia
• LinkedInlinkedin.com/company/laboratoriocristalia

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries11 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Laboratorio Cristalia